Original language | English (US) |
---|---|
Pages (from-to) | 834-849 |
Number of pages | 16 |
Journal | Journal of Clinical Oncology |
Volume | 37 |
Issue number | 10 |
DOIs | |
State | Published - 2019 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Clinical Oncology, Vol. 37, No. 10, 2019, p. 834-849.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Clinical cancer advances 2019
T2 - Annual report on progress against cancer from the American society of clinical oncology
AU - Pal, Sumanta K.
AU - Miller, Michael J.
AU - Agarwal, Neeraj
AU - Marina Chang, Susan
AU - Chavez-MacGregor, Mariana
AU - Cohen, Ezra
AU - Cole, Suzanne
AU - Dale, William
AU - Diefenbach, Catherine S.Magid
AU - Disis, Mary L.
AU - Dreicer, Robert
AU - Graham, David L.
AU - Henry, N. Lynn
AU - Jones, Joshua
AU - Keedy, Vicki
AU - Klepin, Heidi D.
AU - Markham, Merry Jennifer
AU - Mittendorf, Elizabeth A.
AU - Rodriguez-Galindo, Carlos
AU - Sabel, Michael S.
AU - Schilsky, Richard L.
AU - Sznol, Mario
AU - Tap, William D.
AU - Westin, Shannon Neville
AU - Johnson, Bruce E.
N1 - Funding Information: Research funded by the NIH and National Cancer Institute (NCI) has played a pivotal role in advances in cancer prevention, diagnosis, and treatment. In fact, federal funding supported three of the five advances in rare cancers and nearly one third of the studies highlighted in this year’s Clinical Cancer Advances report. Funding Information: Another study looked at the prevalence of oral bacteria in 106 patients with esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC)62 (this study was funded, in part, by NCI). The periodontal Funding Information: Much of the progress we have made against cancer has been driven by federally funded research, and this past year is no different. For example, funding from the US government, including the National Institutes of Health and National Cancer Institute, supported three of the five advances in rare cancers and nearly a third of the studies highlighted in the report. With the number of US cancer cases set to increase by roughly a third over the next decade, it is crucial that our nation continues to invest in the next generation of cures for patients. Funding Information: The federally funded study53 analyzed the blood of approximately 1,000 patients previously diagnosed with cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast and compared those results to blood sample analyses from 850 healthy people. Cancer-SEEK was able to detect evidence of cancer with a sensitivity (the positive results were accurate) of 69% to 98% and a specificity (the negative results were accurate) of greater than 99% (this study was funded, in part, by NCI and the National Institute of General Medical Sciences). The authors suggest that CancerSEEK may be able to be developed as a universal blood test for the early diagnosis of cancer. Funding Information: cisplatin or cisplatin plus sodium thiosulfate treatment (this study was funded, in part, by NIH and the US Department of Veterans Affairs). Sodium thiosulfate is a basic chemical compound that is on the WHO list of essential, safe medicines.58
PY - 2019
Y1 - 2019
UR - http://www.scopus.com/inward/record.url?scp=85063952026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063952026&partnerID=8YFLogxK
U2 - 10.1200/JCO.18.02037
DO - 10.1200/JCO.18.02037
M3 - Review article
C2 - 30702028
AN - SCOPUS:85063952026
SN - 0732-183X
VL - 37
SP - 834
EP - 849
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -